

[The  \$\alpha 6\$  subunit-containing GABAA receptor: A novel drug target for inhibition of trigeminal activation.](#)

Fan PC, Lai TH, Hor CC, Lee MT, Huang P, Sieghart W, Ernst M, Knutson DE, Cook J, Chiou LC.

Neuropharmacology. 2018 Sep 15;140:1-13. doi: 10.1016/j.neuropharm.2018.07.017. Epub 2018 Jul 21.

[Trigeminal neuropathic pain development and maintenance in rats are suppressed by a positive modulator of  \$\alpha 6\$  GABAA receptors.](#)

Vasović D, Divović B, Treven M, Knutson DE, Steudle F, Scholze P, Obradović A, Fabjan J, Brković B, Sieghart W, Ernst M, Cook JM, Savić MM.

Eur J Pain. 2019 May;23(5):973-984. doi: 10.1002/ejp.1365. Epub 2019 Feb 4.

[Cerebellar  \$\alpha 6\$  -subunit-containing GABAA receptors: a novel therapeutic target for disrupted prepulse inhibition in neuropsychiatric disorders.](#)

Chiou LC, Lee HJ, Ernst M, Huang WJ, Chou JF, Chen HL, Mouri A, Chen LC, Treven M, Mamiya T, Fan PC, Knutson DE, Witzigmann C, Cook J, Sieghart W, Nabeshima T.

Br J Pharmacol. 2018 Jun;175(12):2414-2427. doi: 10.1111/bph.14198. Epub 2018 May 10.

[Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the  \$\gamma\$ -Aminobutyric Acid Type A Receptor \(GABAAR\)  \$\alpha 6\$  Subtype with Improved Metabolic Stability and Enhanced Bioavailability.](#)

Knutson DE, Kodali R, Divović B, Treven M, Stephen MR, Zahn NM, Dobričić V, Huber AT, Meirelles MA, Verma RS, Wimmer L, Witzigmann C, Arnold LA, Chiou LC, Ernst M, Mihovilovic MD, Savić MM, Sieghart W, Cook JM.

J Med Chem. 2018 Mar 22;61(6):2422-2446. doi: 10.1021/acs.jmedchem.7b01664. Epub 2018 Mar 6.

[Identification of novel positive allosteric modulators and null modulators at the GABAA receptor  \$\alpha + \beta\$ - interface.](#)

Varagic Z, Wimmer L, Schnürch M, Mihovilovic MD, Huang S, Rallapalli S, Cook JM, Mirheydari P, Ecker GF, Sieghart W, Ernst M.

Br J Pharmacol. 2013 May;169(2):371-83. doi: 10.1111/bph.12151.

[Subtype selectivity of  \$\alpha + \beta\$ - site ligands of GABAA receptors: identification of the first highly specific positive modulators at  \$\alpha 6 \beta 2 / 3 \gamma 2\$  receptors.](#)

Varagic Z, Ramerstorfer J, Huang S, Rallapalli S, Sarto-Jackson I, Cook J, Sieghart W, Ernst M.

Br J Pharmacol. 2013 May;169(2):384-99. doi: 10.1111/bph.12153.

[\$\alpha 6\$ GABAA Receptor Positive Modulators Alleviate Migraine-like Grimaces in Mice via Compensating GABAergic Deficits in Trigeminal Ganglia](#)

Hung-Ruei Tzeng<sup>1</sup> & Ming Tatt Lee<sup>2,3</sup> & Pi-Chuan Fan<sup>4,5</sup> & Daniel E. Knutson<sup>6</sup> & Tzu-Hsuan Lai<sup>5</sup> & Werner Sieghart<sup>7</sup> & James Cook<sup>6</sup> & Lih-Chu Chiou<sup>1,2,8</sup>

Neurotherapeutics, 27 October 2020; <https://doi.org/10.1007/s13311-020-00951-1>

[Reduced GABAA receptor  \$\alpha 6\$  expression in the trigeminal ganglion alters inflammatory TMJ hypersensitivity](#)

J.Puri, P. Vinothini J.Reubena L. L.Bellinger, L.Ailing, Y.B.Peng, P.R.Kramer

Neuroscience, Volume 213, 28 June 2012, Pages 179-190

<https://doi.org/10.1016/j.neuroscience.2012.03.059>